相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment
T. Yuraszeck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Uwe Reusch et al.
CLINICAL CANCER RESEARCH (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
George S. Laszlo et al.
ONCOTARGET (2016)
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
Judith Feucht et al.
ONCOTARGET (2016)
Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy
Mahdi Shabani et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk
Kimberly H. Harrington et al.
PLOS ONE (2015)
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
G. S. Laszlo et al.
BLOOD CANCER JOURNAL (2015)
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
George S. Laszlo et al.
BLOOD (2014)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
RB Walter et al.
BLOOD (2005)
分享论文
